// App-Quantinova.ai

AEP374 : Liraglutide downregulates the expression of miRNA-424 in patients with obesity

Researchers

Presenter

  • Georgios K Dimitriadis

Principal Investigators

  • Federica Dimitri

  • Danielle Bate

  • Bianca Leca

  • Allan Davasgaium

  • Gyanendra Tripathi

  • Alexander D Miras

  • Francesco Rubino

  • Mark Christian

  • Harpal S Randeva

Medical Centers

  • King’s College Hospital, Endocrinology and Metabolism, United Kingdom

  • University of Warwick, Life Sciences, Coventry, United Kingdom

  • University Hospital Coventry & Warwickshire, United Kingdom

  • University of Derby, Derby, United Kingdom.

  • Imperial College London, Hammersmith Campus, United Kingdom

  • Kings College London, London, United Kingdom

  • Nottingham Trent University, Nottingham, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Obesity

Biomarkers

  • N/A

Drug/Treatment

  • Liraglutide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved